Target intelligence / Profile preview

Nutrient excess

Molecular classification
Metabolic state, Physiological condition
01

Overview

Nutrient excess, often termed overnutrition or metabolic overload, is a physiological and pathological state characterized by a chronic surplus of energy intake relative to energy expenditure. This condition leads to the sustained over-activation of nutrient-sensing pathways, most notably the mechanistic target of rapamycin complex 1 (mTORC1), and the concomitant suppression of energy-sensing catabolic pathways, such as those governed by AMP-activated protein kinase (AMPK) [1, 2]. At the cellular level, persistent nutrient excess causes mitochondrial dysfunction, endoplasmic reticulum stress, and the accumulation of toxic lipid intermediates like diacylglycerols and ceramides, which collectively impair insulin signaling [1, 3, 7]. Clinically, it serves as the fundamental driver of the global metabolic disease epidemic, encompassing obesity, type 2 diabetes mellitus, and non-alcoholic fatty liver disease (NAFLD) [10]. While 'nutrient excess' is not a single molecular target, therapeutic interventions for its associated diseases typically involve pharmacological agents that mimic a low-energy state, modulate nutrient-sensing nodes, or enhance insulin sensitivity [5, 7, 8].

Other names
OvernutritionMetabolic overloadNutrient surplusExcess caloric intakeHyperalimentation
02

Mechanism of action

Activation of catabolic regulators (e.g., AMPK activation) or inhibition of anabolic drivers (e.g., mTORC1 inhibition) to mitigate the systemic effects of chronic over-nutrition.

03

Biological functions

AnabolismEnergy homeostasisLipid metabolismSignal transductionCellular growthmTORC1 activation
04

Disease associations

ObesityType 2 diabetes mellitusMetabolic syndromeNonalcoholic fatty liver disease (NAFLD)Cardiovascular diseaseCancer
05

Safety considerations

Insulin resistanceMetabolic inflammation (Meta-inflammation)Oxidative stressEctopic fat depositionPancreatic beta-cell exhaustion
06

Interacting drugs

Metformin

4 more in the full profile.

07

Biomarkers

Blood glucoseGlycated hemoglobin (HbA1c)Fasting insulinSerum triglyceridesHomeostatic Model Assessment of Insulin Resistance (HOMA-IR)C-reactive protein (CRP)

Beyond the preview

Go deeper on Nutrient excess.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nutrient excess.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call